

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for suppressing proliferation of abnormal prion proteins for preventing a development of prion diseases, comprising systemically, orally, intracerebrally or intraspinally administering to a patient in need thereof an essential amino acid having a branched side chain in an amount sufficient to suppress proliferation of abnormal prion proteins and wherein the essential amino acid is selected from the group consisting of isoleucine, leucine, valine and mixtures thereof, wherein said amount is 5-15g/kg body weight wherein said amount is sufficient for preventing development of prion diseases.

2. (Cancelled).

3. (Previously Presented) The method according to claim 1, wherein said amino acid having a branched side chain is leucine.

4. (Currently Amended) A method for providing an essential amino acid having a branched side chain to a patient in need thereof for preventing a development of prion diseases, comprising systemically, orally, intracerebrally or intraspinally administering said essential amino acid having a branched side chain in an amount of 5-15g/kg so as to suppress proliferation of abnormal prion proteins and prevent development of prion diseases wherein said essential amino acid is selected from the group consisting of leucine, isoleucine, valine, and mixtures thereof.

5. (Cancelled)

6. (Previously Presented) The method according to claim 4, wherein said essential amino acid having a branched side chain is leucine.

7. (Currently Amended) A suppressive agent containing an essential amino acid having a branched side chain as an active ingredient for suppressing proliferation of abnormal prion proteins so as to prevent a development of prion diseases, wherein the essential amino acid having a branched side chain is selected from the group consisting of leucine, isoleucine, valine, and mixtures thereof and wherein the essential amino acid in the suppressive agent is 20 to 40 mg/mL of the suppressive agent.

8. (Cancelled)

9. (Previously Presented) The suppressive agent according to claim 7, wherein the essential amino acid having a branched side chain is leucine.

10-12. (Cancelled)

13. (Currently Amended) A method for ~~treating~~ preventing a development prion diseases by suppressing proliferation of abnormal prion proteins which comprises systemically, orally, intracerebrally or intraspinally administering to a patient in need thereof an essential amino acid having a branched side chain as an active ingredient, wherein the essential amino acid having a branched side chain is selected from the group consisting of leucine, isoleucine, valine, and mixtures thereof and wherein the essential amino acid is administered in an amount sufficient to suppress proliferation of abnormal prion proteins wherein said amount is 5-15g/kg.

14. (Cancelled)

15. (Original) The method according to claim 13, wherein the essential amino acid having a branched side chain is leucine.

16. (Previously Presented) The method according to claim 13, wherein said prion disease is scrapie.

17. (Previously Presented) The method according to claim 13, wherein said prion disease is bovine spongiform encephalopathy (BSE).

18. (Previously Presented) The method according to claim 13, wherein said prion disease is Creutzfeldt-Jakob disease (CJD).

19. (Previously Presented) The method according to claim 13, wherein said prion disease is Gerstmann-Straussler-Scheinker syndrome.